Pages 1 - 56

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

)

)

Before The Honorable Jon S. Tigar, Judge

IN RE: CATHODE RAY TUBE (CRT) ANTITRUST LITIGATION.

NO. 07-05944 JST

San Francisco, California Thursday, May 30, 2019

TRANSCRIPT OF PROCEEDINGS

APPEARANCES:

For Direct Purchaser Plaintiffs:

SAVERI & SAVERI, INC.

707 Sansome Street

San Francisco, California 94111

BY: R. ALEXANDER SAVERI, ATTORNEY AT LAW GEOFFREY C. RUSHING, ATTORNEY AT LAW

KELLOGG, HANSEN, TODD, FIGEL & FREDERICK PLLC

Sumner Square

1615 M Street, N.W. - Suite 400

Washington, D.C. 20036

BY: GREGORY G. RAPAWY, ATTORNEY AT LAW

For Indirect Purchaser Plaintiffs:

TRUMP, ALIOTO, TRUMP & PRESCOTT LLP

2280 Union Street

San Francisco, California 94123

BY: MARIO N. ALIOTO, ATTORNEY AT LAW

(APPEARANCES CONTINUED ON FOLLOWING PAGE)

REPORTED BY: Jo Ann Bryce, CSR No. 3321, RMR, CRR, FCRR

Official Reporter

For Indirect Purchaser Plaintiffs: ZELLE LLP 44 Montgomery Street - Suite 3400 San Francisco, California 94104 BY: QIANWEI FU, ATTORNEY AT LAW For Defendants Irico Group Corp. and Irico Display Devices Co., Ltd.: BAKER BOTTS LLP 101 California Street - Suite 3600 San Francisco, California 94111 BY: STUART C. PLUKKETT, ATTORNEY AT LAW BAKER BOTTS LLP The Warner 1299 Pennsylvanie Avenue, N.W. Washington, D.C. 20004 BY: JOHN M. TALADAY, ATTORNEY AT LAW BAKER BOTTS LLP 1001 Page Mill Road Building One - Suite 200 Palo Alto, California 94304 BY: BRIAN JACOBSMEYER, ATTORNEY AT LAW KAYLEE YANG, ATTORNEY AT LAW KAYLEE YANG, ATTORNEY AT LAW For Intervenor U.S. Department of Justice, Antitrust Division: U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW	1	APPEARANCES: (CO	NTINUED)	
44 Montgomery Street - Suite 3400 San Francisco, California 94104 BY: QIANWEI FU, ATTORNEY AT LAW For Defendants Irico Group Corp. and Irico Display Devices Co., Ltd.: BAKER BOTTS LLP 101 California Street - Suite 3600 San Francisco, California 94111 BY: STUART C. PLUNKETT, ATTORNEY AT LAW BAKER BOTTS LLP The Warner 1299 Pennsylvanie Avenue, N.W. Washington, D.C. 20004 BY: JOHN M. TALADAY, ATTORNEY AT LAW BAKER BOTTS LLP 1001 Page Mill Road Building One - Suite 200 Palo Alto, California 94304 BY: BRIAN JACOBSMEYER, ATTORNEY AT LAW KAYLEE YANG, ATTORNEY AT LAW For Intervenor U.S. Department of Justice, Antitrust Division: U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW	2	For Indirect Purc		
For Defendants Irico Group Corp. and Irico Display Devices Co., Ltd.: BAKER BOTTS LLP 101 California Street - Suite 3600 San Francisco, California 94111 BY: STUART C. PLUNKETT, ATTORNEY AT LAW BAKER BOTTS LLP The Warner 1299 Pennsylvanie Avenue, N.W. Washington, D.C. 20004 BY: JOHN M. TALADAY, ATTORNEY AT LAW BAKER BOTTS LLP 1001 Page Mill Road Building One - Suite 200 Palo Alto, California 94304 BY: BRIAN JACOBSMEYER, ATTORNEY AT LAW KAYLEE YANG, ATTORNEY AT LAW For Intervenor U.S. Department of Justice, Antitrust Division: U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW	3		44 Montgomery Street - Suite 3400	
BAKER BOTTS LLP 101 California Street - Suite 3600 San Francisco, California 94111 BY: STUART C. PLUNKETT, ATTORNEY AT LAW BAKER BOTTS LLP The Warner 1299 Pennsylvanie Avenue, N.W. Washington, D.C. 20004 BY: JOHN M. TALADAY, ATTORNEY AT LAW BAKER BOTTS LLP 1001 Page Mill Road Building One - Suite 200 Palo Alto, California 94304 BY: BRIAN JACOBSMEYER, ATTORNEY AT LAW KAYLEE YANG, ATTORNEY AT LAW For Intervenor U.S. Department of Justice, Antitrust Division: U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW	4	BY:		
BAKER BOTTS LLP 101 California Street - Suite 3600 San Francisco, California 94111 BY: STUART C. PLUNKETT, ATTORNEY AT LAW BAKER BOTTS LLP The Warner 1299 Pennsylvanie Avenue, N.W. Washington, D.C. 20004 BY: JOHN M. TALADAY, ATTORNEY AT LAW BAKER BOTTS LLP 1001 Page Mill Road Building One - Suite 200 Palo Alto, California 94304 BY: BRIAN JACOBSMEYER, ATTORNEY AT LAW KAYLEE YANG, ATTORNEY AT LAW For Intervenor U.S. Department of Justice, Antitrust Division: U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW	5	For Defendants Irico Group Corp. and Irico Display Devices Co.,		
San Francisco, California 94111 BY: STUART C. PLUNKETT, ATTORNEY AT LAW BAKER BOTTS LLP The Warner 1299 Pennsylvanie Avenue, N.W. Washington, D.C. 20004 BY: JOHN M. TALADAY, ATTORNEY AT LAW BAKER BOTTS LLP 1001 Page Mill Road Building One - Suite 200 Palo Alto, California 94304 BY: BRIAN JACOBSMEYER, ATTORNEY AT LAW KAYLEE YANG, ATTORNEY AT LAW For Intervenor U.S. Department of Justice, Antitrust Division: U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW	6	nca		
BAKER BOTTS LLP The Warner 1299 Pennsylvanie Avenue, N.W. Washington, D.C. 20004 BY: JOHN M. TALADAY, ATTORNEY AT LAW BAKER BOTTS LLP 1001 Page Mill Road Building One - Suite 200 Palo Alto, California 94304 BY: BRIAN JACOBSMEYER, ATTORNEY AT LAW KAYLEE YANG, ATTORNEY AT LAW For Intervenor U.S. Department of Justice, Antitrust Division: U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW	7	RV.	San Francisco, California 94111	
The Warner 1299 Pennsylvanie Avenue, N.W. Washington, D.C. 20004 BY: JOHN M. TALADAY, ATTORNEY AT LAW BAKER BOTTS LLP 1001 Page Mill Road Building One - Suite 200 Palo Alto, California 94304 BY: BRIAN JACOBSMEYER, ATTORNEY AT LAW KAYLEE YANG, ATTORNEY AT LAW For Intervenor U.S. Department of Justice, Antitrust Division: U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW 18 19 20 21	8	ы.		
Washington, D.C. 20004 BY: JOHN M. TALADAY, ATTORNEY AT LAW BAKER BOTTS LLP 1001 Page Mill Road Building One - Suite 200 Palo Alto, California 94304 BY: BRIAN JACOBSMEYER, ATTORNEY AT LAW KAYLEE YANG, ATTORNEY AT LAW For Intervenor U.S. Department of Justice, Antitrust Division: U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW 19 20 21	9		The Warner	
BAKER BOTTS LLP 1001 Page Mill Road Building One - Suite 200 Palo Alto, California 94304 BY: BRIAN JACOBSMEYER, ATTORNEY AT LAW KAYLEE YANG, ATTORNEY AT LAW For Intervenor U.S. Department of Justice, Antitrust Division: U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW 18 19 20 21	10	PV.	Washington, D.C. 20004	
1001 Page Mill Road Building One - Suite 200 Palo Alto, California 94304 BY: BRIAN JACOBSMEYER, ATTORNEY AT LAW KAYLEE YANG, ATTORNEY AT LAW For Intervenor U.S. Department of Justice, Antitrust Division: U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW 18 19 20 21	11	ы.	·	
Palo Alto, California 94304 BY: BRIAN JACOBSMEYER, ATTORNEY AT LAW KAYLEE YANG, ATTORNEY AT LAW For Intervenor U.S. Department of Justice, Antitrust Division: U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW 18 19 20 21	12		1001 Page Mill Road	
For Intervenor U.S. Department of Justice, Antitrust Division: U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW 18 19 20 21	13	PV.	Palo Alto, California 94304	
U.S. DEPARTMENT OF JUSTICE Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW 18 19 20 21	14	BI:		
Antitrust Division 950 Pennsylvania Ave., N.W Room 3320 Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW 18 19 20 21	15			
Washington, D.C. 20530 BY: NICKOLAI G. LEVIN, ATTORNEY AT LAW 19 20 21	16		Antitrust Division	
18 19 20 21	17	PV.	Washington, D.C. 20530	
20 21	18	ы.	NICRODAL G. DEVIN, ALTORNEL AL DAW	
21	19			
	20			
22	21			
	22			
23	23			
24	24			
25	25			

Thursday - May 30, 2019 1 2:05 p.m. 2 PROCEEDINGS ---000---3 THE CLERK: Your Honor, now calling civil matter 4 5 07-5944, Crago, Incorporated v. Chunghwa Picture Tubes Ltd. 6 If counsel could please come forward and state their 7 appearances for the record. MR. SAVERI: Good afternoon, Your Honor. May it 8 please the Court, Rick Saveri on behalf of the Direct Purchaser 9 10 plaintiffs. 11 MR. RAPAWY: Gregory Rapawy on behalf of the Direct Purchaser plaintiffs, Your Honor. 12 MR. RUSHING: Your Honor, Geoffrey Rushing on behalf 13 of the Direct Purchasers. 14 15 MR. ALIOTO: Good afternoon, Your Honor. Mario Alioto 16 on behalf of the Indirect Purchasers. 17 MS. FU: Good afternoon, Your Honor. Qianwei Fu from 18 Zelle LLP on behalf of the Indirect Purchaser plaintiffs. MR. PLUNKETT: Good afternoon, Your Honor. 19 20 Stuart Plunkett on behalf of the Irico defendants. 21 MR. TALADAY: Your Honor, John Taladay on behalf of the Irico defendants. 22 MR. JACOBSMEYER: Good afternoon, Your Honor. Brian 23 Jacobsmeyer on behalf of the Irico defendants. 24 25 MS. YOUNG: Good afternoon, Your Honor. Kaylee Young

from Baker Botts on behalf of the Irico defendants.

MR. LEVIN: And good afternoon, Your Honor. Nick Levin on behalf of the United States.

THE COURT: Very good. Welcome.

So I'd like to set some time limits. I'm not quite sure how to go about it. I think the arguments made by the Direct Purchasers and the Indirect Purchasers substantially overlap, as do the arguments made by the United States. So that's on the one hand.

On the other hand, I need to give the Irico defendants the opportunity to respond to all the arguments made by everybody. So if I were only concerned about the first -- if I were trying to balance all those things, what I might do is give each side 30 minutes putting three different parties -- Indirect Purchasers, the Direct Purchasers, and the amicus -- on one side and the Irico defendants on the other, but I don't know if that works in injury to the plaintiffs because you probably just are going to need to have some amount of overlap.

So I'll set the minutes willy-nilly in just a moment if I don't hear a better suggestion, but does someone want to make a suggestion that I can adopt that gives everybody enough room to argue? You're the only thing on calendar this afternoon, which doesn't mean I want to here hours and hours of arguments, but it does mean we have a little more time than we might otherwise.

Your Honor, Mario Alioto. 1 MR. ALIOTO: We have met and conferred amongst the plaintiffs and tried 2 to coordinate in advance of coming here today, and we're fine 3 with ceding most of the time to the Direct Purchasers. 4 need a little time at the end; but if that's any help, 5 6 Your Honor, we're fine letting the Directs lead off and take 7 the majority of the time on the plaintiffs' side. THE COURT: All right. 8 MR. SAVERI: Yes, Your Honor, Rick Saveri on behalf of 9 plaintiffs. 10 11 Mr. Rapawy from Kellogg Hansen is going to be handling the motion for the Direct Purchaser plaintiffs, and that would be 12 our proposal, that he'll handle most of the issues; and then if 13 the Indirects needed to pick up something, they'd pick that up. 14 THE COURT: All right. 15 16 Mr. Levin -- am I pronouncing that correctly? 17 MR. LEVIN: Yes, Your Honor. THE COURT: Mr. Levin, how much time would you like? 18 How much time do you need? 19 20 I would say 10 minutes would be great. MR. LEVIN: THE COURT: Okay. What if I give the Direct 21 Purchasers 20 minutes, I give the Indirect Purchasers 5 minutes 22 23 to back cleanup, I give Mr. Levin the 10 minutes he wants, and I give the defendants 30 minutes? That's about an hour and 5 24

It seems like that ought to work out.

25

minutes.

MR. RAPAWY: That sounds fine with us, Your Honor.

THE COURT: Good. So ordered.

I'm going to let the -- I will tell the defendants, these are your motions so you have a right of reply. You have to allocate that yourself by just stopping talking sometime before the 30 minutes is up; and then if you don't stop talking, the 30 minutes elapses, I'll conclude from that you've made the tactical decision not to make a reply argument.

But it's your motion and so you can go first. Before you start -- and it's Mr. Plunkett; correct?

MR. PLUNKETT: That's correct.

THE COURT: Very good. Mr. Plunkett and other persons, before you start, just a couple of observations.

First, as to the -- much is made by the Direct Purchaser plaintiffs and the Indirect Purchaser plaintiffs to the effect of "Your Honor already decided all these issues so just stay right where you are" and that, of course, has some superficial appeal; and if I was them, I'd probably make that argument also. I might not make it as frequently or as strenuously as they do, but I would make it.

Some things were decided subject to further discovery, but they were decided, and some things were simply not decided. So the question of whether there was a direct effect in the United States was decided. That question was decided, and I'm the one who sent the parties off with jurisdictional discovery.

So I don't think it's -- I don't know that it's 100 percent correct that the Irico defendants need to meet the motion for reconsideration standards.

I don't think that's actually helpful to hold these motions up to those particular standards, but I do think it's worth observing that I considered most of the same authorities and not very much different information, and that's the conclusion that I reached.

On the other hand, with regard to the question of whether Irico Display is an organ of the state, I simply didn't decide that question at all. It was urged upon me by the Irico defendants that Irico Display was an organ of the state, and I found that the Zhang declaration, which was the only evidence offered in support of that point, was not -- I was not able simply to consider that declaration. So I simply made a finding that they hadn't met their *prima facie* burden at that stage of the case. So that question, I would say -- on that question there is a much cleaner slate.

And to say just one more thing and to be a little clearer, the fact that I decided on that first point before doesn't mean that I've already decided it. It just means that the defendants have more of an uphill burden or uphill battle.

And then the last thing I would say is these motions obviously are very important to the parties. I don't regard them as incredibly complicated. They're very interesting and

they're very well briefed on both sides, but they don't have that many moving parts. So I look forward to your arguments.

Mr. Plunkett, finally I'll let you have the floor.

MR. PLUNKETT: Thank you, Your Honor, and thank you for that guidance. I look forward to the uphill battle when I get to that commercial activity exception.

I'm here to respond primarily to the -- on the four motions to dismiss. As you've noted, there is a lot of overlap. Mr. Taladay is here principally to respond to anything DOJ might raise. There is a lot of overlap. Subject to Your Honor's instructions, I've said I'm not going to be insulted if anybody jumps up when I can't answer a question or I'm failing to make a point.

But what I plan to do now -- and someone's going to give me the hook hopefully after 10 or 15 minutes -- is talk about the three main issues in the case. The first has to do with whether Irico made sales in the U.S. The second has to do with whether the commercial activity exception applies, and I'm going to address directly the uphill battle because I think there's no problem, Your Honor, getting up that hill. And then the third is one that applies to just two of the motions, and that's whether Irico Display qualifies as an organ.

On the first argument, we have always said, since our first filing in this case, that Irico Group and Irico Display made no sales in the United States and that remains absolutely

```
There is no evidence whatsoever of any transaction
 1
     true.
     between Irico and any U.S. entity period. Irico was set up by
 2
     the Chinese government to make sales domestically and that is
 3
     largely what they did.
 4
 5
          Plaintiffs try to muddy this up in a few ways.
                                                          The most
     significant and troubling of which is their reliance on about
 6
     $7 million in sales into the United States by an entity
 7
     called -- I'm going to do this for the court reporter's
 8
     benefit -- China --
 9
10
              THE COURT:
                         Isn't it 8 million?
11
              MR. PLUNKETT:
                             It may be 8 million.
              THE COURT: I think Mr. Saveri thinks it's 8.
12
13
              MR. PLUNKETT: Let's go with 8 because it wouldn't
     matter if it was a hundred million --
14
15
              THE COURT:
                          Okay.
16
              MR. PLUNKETT: -- because of what I'm about to say.
17
          So the entity is called the China National Electronics
18
     Import and Export Caihong Company; Caihong spelled
19
     C-A-I-H-O-N-G. I think everyone here today will refer to that
20
     entity by an acronym CNEIECC, which is C-N-E-I-E-C-C.
21
          CNEIECC is an unrelated state-owned entity that was not
22
     owned in any part by Irico Group or Irico Display during the
23
     relevant period.
              THE COURT: There's a declaration that says that;
24
25
     right?
```

There's a declaration that says that. 1 MR. PLUNKETT: 2 THE COURT: And then there's some pieces of paper that say otherwise. 3 MR. PLUNKETT: There are three pieces of paper that 4 5 plaintiffs rely on, unfortunate documents that were created by individuals who didn't --6 7 THE COURT: Why would someone make that up? MR. PLUNKETT: I don't know, but they --8 THE COURT: No, no. Let's stop here. I mean, I love 9 we're off to a good humored start and that sort of augers well 10 11 for everyone's afternoon, but let's really focus on this question for a second. 12 13 What possible motivation could someone have had to sit in a room and say, "I know what I'll do. I'll put CNEIECC in an 14 15 org. chart where it doesn't belong"? 16 MR. PLUNKETT: I don't know their motivation, but I 17 can give this perspective. In a huge pile of documents, there 18 were three instances where the ownership was misstated, but 19 plaintiffs can't make a fact true by relying on documents that 20 are mistaken. Instead, where the Court should look is to the official Chinese records, which show that in 2014 after the 21 22 class period, 100 percent of CNEIECC was transferred by its

How could that transfer have taken place in 2014 if Irico
Group had owned any part of CNEIECC before 2014? I don't think

100 percent owner to Irico Group.

23

24

25

plaintiffs can stand up here --1 THE COURT: Well, lots of things could have happened 2 before 2014. I mean, it's not as though -- it's not like chain 3 of custody. It's not like I know what was happening with that 4 5 entity every day. And so if someone says in 2000 -- and I don't remember what date this -- and, by the way, for the 6 plaintiffs, there was many, over a hundred-page exhibit in 7 which that single page showing those sales was located and 8 nobody gave me the page number so it took me a little while to 9 10 find. 11 But, anyway, whatever year that was from, lots of things could happen in terms of ownership change; right? 12 MR. PLUNKETT: Nothing did happen, Your Honor. 13 The historical records that we've cited show that CNEIECC was 14 15 created and at the time it became a wholly owned subsidiary of 16 an entity that has another acronym, the China National 17 Electronics Import and Export Corporation. It became a wholly 18 owned subsidiary of that entity, which I will call CEIEC, 19 C-E-I-E-C, in 1987 and it remained as such until 2014. 20 THE COURT: Who produced the document that contains

THE COURT: Who produced the document that contains the organization chart?

21

22

23

24

25

MR. PLUNKETT: We would have produced that document.

We produced all documents that we had that related in any way.

THE COURT: So one of the Irico entities did that?

MR. PLUNKETT: We produced those documents, yes,

Your Honor. 1 2 THE COURT: Right. Okay. MR. PLUNKETT: But, again, we think the only -- it's 3 an objective question and so the place to look is the public 4 5 record in China of this transaction and ownership. Let's say I wouldn't have a job if my clients had 6 7 perfectly consistent documents over multiple years, but I -and I will also note that the references, even in those 8 documents, are -- they're all -- none of them are consistent. 9 One says, you know, that it's a branch, and so they're even 10 11 inconsistent. The only thing that is consistent is the public record. 12 I would also note, just as sort of icing on the cake, that 13 even if CNEIECC were a related entity and its sales counted as 14 15 our sales, which they don't, none of the sales they cite are 16 relevant. They all concern irrelevant products. They don't --17 some of the products don't contain CRTs. They were not shipped to the U.S., and one of them is about a sample sale where the 18 products were sent back to China. 19 20 Isn't it about 2,000 units, that sample THE COURT: sale? 21 22 MR. PLUNKETT: Yes.

THE COURT: Yeah, I think about that transaction a little differently.

23

24

25

MR. PLUNKETT: Yeah. And that all of those sales,

though, are CNEIECC so they're not Irico sales. And plaintiffs don't even make an effort to say, nor could they say, that those sales could be attributed to us under some theory of alter ego or agency.

The other way that plaintiffs try to muddy the water on this no U.S. sales issue is by talking about Irico (USA).

There is a complicated and somewhat unclear story about this entity, but the following facts are true and it makes Irico (USA) Inc. completely irrelevant. It never acted as an agent for sales from Irico Display, there are no evidence that it sold Irico CRTs, and all of the purchases in the record that Irico U.S. made were from CNEIECC, the unrelated entity. And what is more, every single sale went to a different country, not to the U.S. So Irico (USA) is not relevant here.

Finally, IPPs launch an argument and say Irico had knowledge of indirect sales, Irico knew that customers it was selling to in China were selling into the United States; but without going through each exhibit in detail, I will make the following representations, which were in our reply brief. Not one of IPPs exhibits establishes Irico's knowledge of sales in the U.S.

Number two, the IPPs have no evidence that any Irico product, any Irico CRT, ever wound up in a product that was sold in the United States. After a year and a half of discovery with us --

Say that sentence again, please. 1 THE COURT: IPPs have no evidence of an indirect 2 MR. PLUNKETT: sale, essentially that an Irico CRT wound up in a product that 3 was sold in the United States, and that's after many, many 4 5 years, as Your Honor knows, of discovery of multiple of defendants, including manufacturers who sold in the 6 7 United States. All they can come up with is this hodgepodge of e-mails that suggest maybe there was a sale. If they -- if 8 there had been a sale, they would have the evidence of that. 9 I'd like to move to the second issue, the commercial 10 11 activity exception. To fit within this exception, Your Honor, in the Ninth Circuit under the Terenkian case, there has to be 12 a direct connection between the act and the effect without any 13 intervening object, cause, or agency. 14 15 This generally means, for example, that the U.S. must be 16 the place of performance of a contract or needs to be the place 17 where a contract -- or the actions of defendants would result in a breach of contract with a United States resident. 18 In 19 other words, there's generally --20 It's not a contract case. THE COURT: 21 MR. PLUNKETT: Say again? It's not a contract case. 22 THE COURT: 23 This is not a contract case. MR. PLUNKETT:

THE COURT: One of the places -- one of the points of

friction this afternoon -- and I thought the United States

24

25

amicus brief was very helpful on this point -- was the question of whether there need to be, as your clients say, direct sales into the United States.

MR. PLUNKETT: Right. We think that in this case direct sales are the only thing -- in an antitrust case like this, direct sales by our client would be the only type of conduct that could possibly satisfy the commercial activity exception.

So -- right. So what I'm going to get to is that because there's no sales, I think we're probably all going to agree that the question under the commercial activity exception is whether it is enough that we participated in a conspiracy that raised global prices, including in the U.S., causing U.S. customers to pay higher prices. That's the theory they have to proceed on and that's the question under the Foreign Sovereign Immunities Act: Is that enough to show a direct effect?

THE COURT: Now, you and I can agree that under the FTAIA there are circumstances in which -- putting the question of state actor to one side -- okay? -- we'll take the Foreign Sovereign Immunities Act off the table, but otherwise that might be sufficient to hold a defendant in the case under the FTAIA; correct?

MR. PLUNKETT: There are FTAIA cases that come close to that. I can distinguish each one of those on the basis that all of them --

THE COURT: I can't tell what you think the answer to my question is.

MR. PLUNKETT: I think the answer -- I think it's no.

THE COURT: Okay.

MR. PLUNKETT: I think the answer is no because the FTAIA precedent is all distinguishable on the basis that there were direct sales. But I think the more important issue is that the FTAIA precedent cannot be applied to the Foreign Sovereign Immunities Act for several reasons, and that's the hill.

THE COURT: Well, that is not where I was going. I know you think that.

MR. PLUNKETT: Okay.

THE COURT: And had you said yes to my other question,
I might have wondered aloud, let's say I'm a French company and
I'm engaged in this conspiracy and I'm not a state actor, I'm a
privately held company, or what we would in this country call a
public company. I can engage in this antitrust tortious
conduct and I'm liable.

And common users of the term "commercial activity" would immediately characterize what I'm doing as commercial activity, and so then that begs the question: What is it about the way we use that term in the Foreign Sovereign Immunities Act context that would make it not apply here?

But you didn't answer the question that way so I won't ask

you that question, but now you know I'm thinking that.

MR. PLUNKETT: Okay. Now I know what you're thinking.

In that case with a private company, they don't -- their source of personal jurisdiction in a U.S. court is not the Foreign Sovereign Immunities Act.

THE COURT: Right.

MR. PLUNKETT: Rather, it would be, you know, all of the due process precedent or the long-arm statute of the specific state where they were sued and due process limitations.

When it's a foreign sovereign, as it is here, the source of personal jurisdiction is the Foreign Sovereign Immunities

Act; and so in the Ninth Circuit, personal jurisdiction standards have to be met under the commercial activity exception.

THE COURT: Actually now that I think about it, that thought that I uttered is not that helpful because "commercial activity," that phrase is not really where the action is this afternoon. Direct effect is really where the action is.

MR. PLUNKETT: Yeah. I agree with that.

I'd like to make my points on why, even though we think those FTAIA cases are distinguishable and don't stand for the proposition that conspiracy is enough -- I'll use that shorthand -- those principles, even if they did exist under the FTAIA, cannot and should not be applied under the Foreign

Sovereign Immunities Act.

The statutes use very different language. They have the single words "direct" and "effect" in common, that's true, but they have very different purposes. The FSIA is jurisdictional. It's not an antitrust statute. It applies in personal injury, contract, and antitrust cases alike, and it is the only source of jurisdiction over a foreign sovereign.

The FTAIA couldn't be more different. It is an antitrust statute that informs the merits of the case and adds additional elements to Sherman Act claims involving foreign trade.

For that reason, courts do not conflate the two statutes. A search for -- a search in Supreme Court cases, Ninth Circuit cases, and all district courts within the Ninth Circuit turns up only three decisions that even mention FTAIA and FSIA in the same decision. One of those is irrelevant so I'm not going to talk about it, the other one is this Court's order setting aside the default in this case, and the third one is a Ninth Circuit case called LSL Biotechnologies.

In LSL Biotechnologies, there's one paragraph where the court says: This is an FTAIA case and we need to define the word "direct." It just so happens that the Supreme Court just did that in the Weltover case so we're going to use that definition.

There's no discussion by the Ninth Circuit that these statutes are -- that these statutes are comparable or they

should -
THE COURT: I don't know if Mr. Taladay's note already

told you this, but you've been going about 15 minutes.

MR. PLUNKETT: Yeah, he did just tell me that. I'm going to finish this point up and then sit down before I get yelled at.

So LSL Biotechnologies --

THE COURT: For the benefit of the record, I'm not going to yell at you. I don't know about Mr. Taladay.

MR. PLUNKETT: I was referring to Mr. Taladay for the record.

LSL Biotechnologies cannot bear the weight that plaintiffs and the DOJ want to put on that paragraph that these statutes can be read together. That one paragraph in the Ninth Circuit case caused several other courts in the Second and Seventh Circuit to say, "Wait a second, Ninth Circuit. These statutes are very different."

And then the final point I'm going to make is that there are five Ninth Circuit cases which hold that under the direct-effect standard, you have -- under the exception, you have to consider personal jurisdiction standards. They are part of the direct-effect standard.

And plaintiffs have said that the Supreme Court overruled that line of cases in Weltover. Nothing can be further from the truth. It's the one case I brought up here to read. It's

```
I'm not going to read it, but it does -- what the
 1
     very short.
     Supreme Court does in that case is actually apply due process
 2
     standards when considering the commercial activity exception.
 3
     It not only didn't overrule what the Ninth Circuit had held, it
 4
     followed it.
 5
 6
          And I'll reserve the rest of our time. Thank you,
     Your Honor.
 7
              THE COURT: Thank you, Mr. Plunkett.
 8
          Mr. Taladay. Or do you want to wait and save it for reply
 9
     to after Mr. Levin has put his oar in the water, or what do you
10
     want to do?
11
              MR. TALADAY: Yes, I prefer to do that, Your Honor.
12
13
              THE COURT: Very good.
                                      Okay.
          Let me hear, then, from the plaintiffs.
14
15
              MR. RAPAWY: Thank you, Your Honor.
16
          And may it please the Court, I would like to start with
17
     the --
18
              THE COURT:
                          Is it Mr. Rapawy?
              MR. RAPAWY: Yes.
19
20
              THE COURT: Very good.
21
              MR. RAPAWY: Thank you, Your Honor.
22
          I would like to start with the organ question, Your Honor,
23
     which you had described as being open. I think it is a
     complicated one because there are a number of factors, but
24
25
     ultimately those factors all point in our direction.
```

Display was -- I'm sorry -- was not an organ of the

Chinese state in November 2007 because it was engaged in a

characteristically private activity of manufacturing and

selling display tubes to earn profit for its shareholders. And

at that time in 2007, its shareholders were more than two

thirds private. So the majority of its profits and the

majority of its assets were going for private benefit.

That is the overarching question of whether it is engaged in a public or private activity, which the six factors that are applied by the Ninth Circuit in cases such as *Powerex* and *Patrickson* are meant to inform. And when you walk -- then go ahead to walk through those six factors, each of them continues to point in the same direction of saying this was a company that was engaged in private and not in public activity.

The first factor, as Your Honor knows, is the circumstances of Display's creation, and we think that the controlling document there is the 2006 version of the Articles of Association. Your Honor will recall that in your previous opinion we had tried to rely on the 2008 version. You said that you needed to see something from before the filing of the complaint, quite correctly. We now have the 2006 version. It is quite unambiguous that this is a standardized joint stock company formed under the same laws that apply to all Chinese companies, whether private or public, the company law and the securities law.

There's some further explanation of that legal framework in our expert declaration by Professor Milhaupt. So in our view that factor points in our favor.

And even if you were -- and, now, Display will say that you should look at the earlier documents, the ones from 1992 and 1995, in which they were originally set up as a majority -- in fact, as a wholly owned public company and then there was private investment allowed, but I think that the correct approach is to look at it at the time of the filing of the complaint. And we've cited the *Janvey* case from the Fifth Circuit in our briefs on that point, and I think it is persuasive.

The second factor is the purpose of the activities, and this in some respects is sort of a miniature version of the overall question, whether the purpose is a public purpose or a private purpose. And we maintain that making profit for a largely private shareholder is a private purpose, and that that was the -- and the record -- in the record Display is consistently described as a competitor in the market with other companies and as attempting to meet demand and maximize its sales and maximize its revenues and minimize its costs in the same way.

THE COURT: I think you probably win on this point.

MR. RAPAWY: Understood.

THE COURT: I'm just telling you. I mean, I think

about this question of, well, you have to build a hospital or you've got to build a school or something. You know, there are lots of instances in which, particularly in even slightly more regulated economies than the one we have in the United States, in which the government will require corporations to do certain things that produce a public benefit. "You have to build this blah, blah, blah before we'll let you, you know, relocate here," that sort of thing.

And the idea that making their workers better off is a public benefit, all corporations that pay their workers make their workers better off. I really think the fight today is going to turn out, for the most part, to be about direct effect.

MR. RAPAWY: Okay, Your Honor.

THE COURT: That's not the only issue but it's by far the biggest one.

MR. RAPAWY: I can certainly move ahead to that if Your Honor would prefer.

On the question whether they had to build hospitals,

Your Honor, a factual point that I think I would like to assert

against the reply is Display itself does not build hospitals.

It was Group that built hospitals and one-third of Display's

profits went up to Group to use for that if it wanted to.

Very briefly on the rest of the factors, the independence from the government, we think that is largely controlled by the

Articles of Association that have very strong independence language in them; and their corporate representative, as we explain in our brief, adopted the relevant parts of the Articles and of their 2007 annual report. All this very strong independence language, when we got him on the stand or at the table, he said, "Yes, what's written is just how it is." And I think that the declaration that they rely on to the contrary is neither based on personal knowledge nor at all persuasive in light of those concessions.

On the fourth factor, which is financial support of the government, we rely on the figures from their own annual report to show that it was less than 1 percent of their operating revenues in 2007.

On the fifth factor, there's no contention that most of their employees were civil servants. There's an argument about the senior management, but I think we have the better of that one; and even if we don't, I don't think it matters.

THE COURT: Jo Ann, can you type that fast?

THE REPORTER: Yes.

MR. RAPAWY: I will attempt to slow down, Your Honor.

My apologies.

And then the sixth factor, the special privileges and obligations, things like being immune from taxes, being immune from private suit, they don't have any of that under Chinese law and they don't claim to.

On the direct-effect point, Your Honor, we do maintain that the overall principle is that where a defendant is engaged in a global cartel and where the United States is a major market for the products that are price fixed or products as to which the price fixed products are a substantial cost component, that is sufficient. They know that they are changing prices in the United States through their actions overseas, and that is enough for jurisdiction under either of the FSIA or the FTAIA or, for that matter, the due process clause.

A defendant that is engaged in one of these cartels simply cannot say in a U.S. court, "Well, I may have fixed prices in your country -- that affected your country, but you have no jurisdiction over me."

I think that that -- that the argument that the FSIA requires direct sales is almost entirely foreclosed by the language of the statute.

THE COURT: I have it open in front of me.

MR. RAPAWY: Well, Your Honor, as you know, then, there are --

THE COURT: Is it possible that you're about to refer to the fact that subsection (2) focuses on an act performed in the United States and that subsection (3) focuses on an act outside the territory of the United States?

MR. RAPAWY: It was possible, Your Honor; and if

Your Honor does not find that point persuasive, I'm happy to go on.

THE COURT: No, no, no. I'm acknowledging the point in advance of its having been made. So you can make the argument. I want to hear what you have to say. This is the thing I was probably thinking about when I got on the bench this afternoon.

MR. RAPAWY: Very good, Your Honor.

Well, I do think the text is in just the way Your Honor has suggested it is. If not controlling, it gets us almost all the way there all on its own and then the case law from the Ninth Circuit, the *Hsiung* case, which is an FTAIA case.

And I do want to address the question -- the question as to whether direct effect under the FTAIA and under the FSIA should be given different meanings. And I think that if you look at LSL Biotechnologies, which I know Your Honor has because you already cited it, and if you look at the way that that test is further applied in Hsiung, you see that what those cases are doing is they are taking the definition of "direct effect" from Weltover, which -- and Weltover itself is an FSIA case -- and they're saying applying that definition, it is met under these fact patterns that are not really distinguishable from our own.

So, Your Honor, if there were doubt about whether the FSIA and the FTAIA should have different definitions of "direct,"

then that might mean that the Ninth Circuit's analysis in LSL or in Hsiung was not correct, but those cases would still help us because they were applying the Weltover standard and the Weltover standard is unquestionably controlling here.

We've also cited the Flat Panel case, which I think is persuasive, from Judge Illston on the same point. And then we have the Sea Breeze case, which is under the FSIA itself. When we were last before Your Honor, actually Your Honor found that case so I can't take really credit for finding it, but you had relied on the district court case. It's now been affirmed by the Ninth Circuit. There is a footnote in the Ninth Circuit decision saying they agree with the district court's analysis. The district court's analysis is directly on point here.

There is an attempt in the reply to distinguish Sea Breeze by suggesting that there were breaches of contract in that case, and there are not breaches of contract here in the United States; but I believe that if you refer to those cases, you will see that in Sea Breeze, the breaches of contract were not breaches of contract by a Mexican foreign sovereign entity in the United States but, rather, the Mexican foreign sovereign entity breached a case -- breached a contract with an intermediary called Innofood and then Innofood breached the contract with Sea Breeze, which was the United States entity.

So after taking that into account, the case is still directly inconsistent with the direct sales requirement or

direct breach of contract requirement that they claim controls here.

Their cases do not support a direct sales rule, the ones that they cite. I will rest on the briefs on that point unless Your Honor wants to talk about one of the cases that they cite.

I think the facts that we have, based on the licensure report and on the meeting e-mails, show that there was at least awareness of effect on the United States market and that that is enough under the FSIA and FTAIA standard.

On the question of whether the minimum contacts requirement is incorporated, I think the best reading of Weltover is that it is not, and I think the discussion of the due process requirement in Weltover does not conflict with that. Because what the Ninth Circuit -- excuse me -- what the Supreme Court did in Weltover is it first did the statutory analysis under the FSIA, and then it went on to say "It's argued that there's a constitutional problem here, but we don't have to reach that question because there would have been the normal contacts anyway."

If, as Irico has claimed, the direct contacts -- or the minimum contacts requirement were part of the FSIA requirement, then they would have done it as part of the statutory analysis, not as a separate means of avoiding the constitutional question.

That said, if there is doubt about that, I think we have a

very good case for minimum contacts in the United States based on Judge Conti's earlier analysis even without direct sales. It don't think that direct sales are required under the due process clause, and so Your Honor could certainly tie that point off completely by finding, as the Supreme Court did in Weltover, that on these facts we have minimum contacts regardless of whether it's required.

On the question of whether there were direct sales in the United States and this whole issue with the intermediary, which we've called import/export in our briefs, and the Irico (USA) entity, we rely on this evidence not to attempt to attribute those sales up the chain by piercing every veil, but to reinforce our showing that when they entered into the cartel and when they fixed the prices, they were well aware of the effect that that would have on U.S. prices because they were watching the U.S. market trying to get into the market and through the subsidiary, I would say, even making a few sales in the U.S. market.

And I'm referring to a -- especially to these so-called sample sales. I don't think the record compels the conclusion that there were samples -- those were samples. Excuse me. They do say they were samples, but we have an invoice showing the sale. They do not have any documentation or evidence showing that they took those products back. They do not have a witness to say that and they don't have an exhibit to say that

unless I have missed something, Your Honor.

THE COURT: Well, I'm sure they'll say on reply if they think you did miss something.

MR. RAPAWY: I'm sure they will, but I didn't find one when I was preparing for this so I'll look forward to hearing if I missed something.

And so a mere representation from counsel, while I'm sure they believe it to be true and they're stating it as fact --

THE COURT: But there's participation in these meetings, which is not -- the participation in the meetings discussing the conspiracy, this also is not disputed in the record. It doesn't need to be for today's purposes, but it's not disputed I don't think.

MR. RAPAWY: I agree, Your Honor.

THE COURT: I'm saying that out loud because also I would like to be corrected on reply if what I just said is wrong.

MR. RAPAWY: Your Honor, if they were to dispute the participation in those meetings, it would be for the first time today with one exception. There was a footnote in the reply in which they say that we didn't show that Display had employees present at those meetings.

And I was surprised to see that because one of the people who was present at those meetings -- at a number of those meetings was Mr. Wang Zhaojie, who was their declarant on

behalf of Display and their 30(b)(6) representative on behalf of Display and who they claim had extensive familiarity with Display because he was responsible for running Display's overseas sales.

Now, he may not technically have been an employee of Display, in fact he was not, but I think it is a reasonable inference from the fact that they have described this intimate knowledge that he had of Display's activities and the fact that he was present at these meetings.

And I can cite you for examples to the 2017 Saveri declaration, Exhibits 13, 14, 19, 21, 23, 30, and 32. He was present at all of those. So the idea that Display didn't know what was going on at these meetings is, I think, Your Honor, not credible on this record.

I did want to make one additional point in response to something that --

THE COURT: Knowing that -- I mean, this is a little bit of a frolic, but knowing that a conspiracy was discussed at a meeting doesn't make you a participant in a conspiracy under any version of conspiracy law that I'm aware of, does it?

MR. RAPAWY: Well, but the question -- I mean, so that on the merits question we have to prove that they participated in the conspiracy; but for the personal jurisdiction question, we have to prove that they were aware of the -- well, we do have to prove that they participated in the cartel, and I do

think you can infer that from the documents.

But the main point I'm making is that, you know, the claim that Display didn't know what was going on in the United States is --

THE COURT: Hard for you to believe.

MR. RAPAWY: It is hard for me to believe, Your Honor.

I hope it's hard for you to believe as well.

And the one last point I wanted to make in response to something that Mr. Plunkett had said was that he had said that Irico was set up for domestic sales. If you refer to page 247 of their 2007 annual report, which is one of our -- one of our exhibits -- no, no. I'm sorry. It's Amended Plunkett Declaration, Exhibit 2. It's the 2007 annual report. You will see that there's a note there that 21.5 percent of Display sales were overseas.

So maybe that is them consolidating something from another entity, but based on the annual report itself, this is clearly an entity that believed itself to be doing business in the export market consistent, frankly, with all of the meeting e-mails and discussions.

THE COURT: Let me come at this a slightly different way. Wasn't Group -- to the extent that Group was involved in the conspiracy, was there any other manufacturers of CRTs to which they could have been referring when they were making their promises to keep prices high other than Display?

I don't think so, Your Honor. 1 MR. RAPAWY: Okay. I mean, I think that's the point. 2 THE COURT: I'm happy to take the correction, MR. RAPAWY: 3 Your Honor. I think that's an excellent way to put it. 4 5 Unless you have further questions, I think I'll probably turn it over to Mr. Alioto at this point. 6 7 THE COURT: All right. Very good. MR. RAPAWY: Thank you, Your Honor. 8 THE COURT: Mr. Alioto. 9 MR. ALIOTO: Thank you, Your Honor. 10 11 I just wanted to make one point about the record that we have before Your Honor. This is unusual. Usually this type of 12 motion would come up at the inception of a case. Here we have 13 a complete trial, pretrial record. We have a case prepared for 14 15 trial and a full record. 16 And I wanted to just emphasize on this question of direct 17 effect, you couldn't have a fuller picture of that, and I'm 18 sure these other cases that raised these questions at the inception of the case have no record anything like what we have 19 20 here. 21 The Indirect Purchasers --THE COURT: It is a little strange. Can I just say 22 23 it's a little strange? I reread my February 2018 order before

it's a little strange? I reread my February 2018 order before

I took the bench, and it just offhandedly says, "Well, the DPPs

want discovery so everybody can have discovery." But in 99 out

24

25

of 100 other cases, that order would have been the end of it, 1 and we would have just started litigating --2 MR. ALIOTO: Yes. 3 THE COURT: -- but that's okay. 4 5 MR. ALIOTO: Yes. THE COURT: And next time the DPPs will say, 6 7 "Your Honor, we're withdrawing our request for discovery if you rule a certain way." So... 8 MR. ALIOTO: And although the record is complicated 9 and there's quite a bit of factual material in the record, I 10 11 think it does make Your Honor's life a little easier because we're not talking about allegations here. We're not talking 12 about we believe there was a direct effect on the United States 13 or we think or we have alleged. 14 We, the IPs and the DPs as well, the Direct Purchasers, 15 16 have prepared a case and you have before you the highlights of 17 that case and you have before you, for example, in the Indirect case our expert report, a report that said there were meetings, 18 a report that summarized the evidence, a report that went so 19 far as to say that "I've reviewed all of these documents and I 20 have done my economic work and I have done my econometrics, and 21 I determined that there was impact in the United States, there 22 23 was impact on purchasers in the United States." That is -- that's the essence of what we're dealing with 24 25 That's direct effect, not a sale here or a sale there; here.

impact in the United States. And we have it based on the evidence and based on expert testimony. We have that in front of Your Honor.

Furthermore, and this is something you don't get on these motions because of the way they come up at the beginning of the case, you have our expert, and I believe the Direct's expert as well, opining on percentage overcharges. I believe it's 9 percent on picture tubes and double digit on -- 9 percent on television, 25 percent on computer monitors. You do the math. 9 percent, 25 percent on the amount of sales involved, sure, their sales are in the millions of dollars that we know of so far. We haven't had as much discovery on that as we would like and we intend to get that, but you figure their sales in conjunction with the sales of all of the other defendants because it's joint and several liability on all of the sales, you apply those overcharges to those sales, 9 percent and 25 percent, and you can see you're talking about damage in the billions of dollars to purchasers in the United States.

That is the direct effect, not an allegation, not my idea of what's going on, but after several years of discovery, that is the evidence.

And I think that makes Your Honor's job -- I hope it makes
Your Honor's job a lot easier to come to the conclusion that
there was this direct effect and that the commercial activity
exception would apply and that the motion would be denied on

those grounds. 1 2 THE COURT: Thank you. MR. ALIOTO: Thank you, Your Honor. 3 THE COURT: Mr. Levin. 4 5 May it please the Court, first off, we MR. LEVIN: 6 welcome the -- or we appreciate the ability to appear here today to address the proper legal framework governing the FSIA. 7 We only have a couple points to make on the organ prong. 8 THE COURT: I just completed a term, a three-year 9 term, as the judicial representative to the American Bar 10 11 Association section on antitrust laws. I was the judicial representative and in that role I got to appreciate to a very 12 great degree the role that both the Antitrust Division and the 13 Justice Department and the Federal Trade Commission play in the 14 15 enforcement of the United States antitrust laws, and so it's my 16 pleasure to welcome you here today and listen to what you have 17 to say. 18 Thank you, Your Honor. We appreciate MR. LEVIN: 19 that. 20 On organ we only have two brief points. We disagree with two of the Irico defendants legal arguments. First, a company 21 is not an organ simply because it makes money for the state as 22 a shareholder. If that were sufficient, the companies in 23 Patrickson would have been organs. 24 25 Second, foreign state control --

```
Say the name of the case again.
 1
              THE COURT:
                         Patrickson versus Dole Foods.
 2
              MR. LEVIN:
              THE COURT:
                          Right.
 3
                          And, second, foreign state control is not
 4
              MR. LEVIN:
 5
     self-sufficient for organ status. A foreign state could
     control -- wholly control an ordinary commercial enterprise,
 6
 7
     and for this I would point the Court to the Victor Fine Foods
            In there the processing plant was wholly owned by the
 8
     state indirectly and, thus, controlled by it but it wasn't an
 9
10
     organ.
11
          So on both of these points, this is why the relevant
     inquiry is holistic looking at all the relevant factors and not
12
     a single factor. Other than that, on organ we're content to
13
     rest on our submission.
14
          On direct effect, we appreciate -- we're glad that you
15
16
     found our submission useful. I'd like to say a few remarks
     that are mostly directed at the RICO [sic] defendants' reply,
17
18
     and then I'd also like to --
                         I think they said "Irico."
19
              THE COURT:
                               The Irico defendants' reply.
20
              MR. LEVIN:
                          Oh.
                                                              Then --
              THE COURT: You're in the Justice Department.
21
22
     used to saying the word "RICO," but I think it's Irico.
23
                          I've been told better and I should have
              MR. LEVIN:
     known it's Irico. Thank you.
24
25
          But I'd also like to get to the Court's question on why
```

the FTAIA is useful in this specific context here.

On direct effect, we're here for the limited purpose of asking the Court to reject the Irico defendants' argument that a foreign state must make sales in the U.S. to fall within the third prong.

And as this Court recognized based on a reading of the statute, sales in the United States already fall within the first prong or the second prong. The Irico defendants never explain what -- under their proposed rule, what would fall in the third prong but not the first, and we respectfully submit that their proposed rule robs the third prong of any meaningful function.

In support of their proposed rule, the Irico defendants advance three incorrect arguments. First, that it's required by precedent; second, that it's necessary to render the statute constitutional in order for there to be sufficient minimum context --

THE COURT: Would you hold on a moment, please.

MR. LEVIN: I'm sorry?

THE COURT: Just hold off a second. I'm making a note of something you said.

(Pause in proceedings.)

THE COURT: Thanks. Go ahead.

MR. LEVIN: Second, that it's necessary to render the statute constitutional; and, third, that it's -- that their

proposed rule is necessary for there to be a legally significant act in the United States giving rise to the claim. We respectfully submit that each of these three arguments are inconsistent with Ninth Circuit precedent.

First, their proposed legal rule is not mandated by precedent, and we respectfully submit that it's flatly inconsistent with the *Sea Breeze* case in which the foreign state defendant, ESSA, made no sales in the United States.

Second, a defendant need not make -- assuming that minimum contacts apply, a defendant need not make sales in the United States to have minimum contacts with the United States, and this is made clear by the *Schwarzenegger* case that they cite, which says that purposeful direction at a forum is sufficient for minimum contacts even absent a sale.

Third, a defendant does not need to make sales in the United States for there to be a legally significant act in the United States giving rise to the claim, and this is made clear by the Lyon case that we cite in our statement of interest. In that case, the legally significant act in the United States was the plaintiff's death, not the sale of the defective helicopter, which was entirely abroad.

As for the Court's question on the FTAIA, we think it's useful because of the way the Court applied the direct-effect requirement in *Hsiung*, and its useful for the limited proposition just as support, it's not binding, but for the

notion that price fixing of a component product can have a

direct effect on the price of finished goods in the

United States even if the fixing of the component prices was

entirely abroad.

THE COURT: So I want to go back to a couple of points you just made in reverse order.

So, first, you were talking about a legally significant act in the United States. I gather that in the view of the Department of Justice, that in an antitrust conspiracy case, the legally significant act is a consumer injury in the form of higher prices; correct?

MR. LEVIN: Yes, Your Honor.

THE COURT: And you tried, with mixed success in your brief, to avoid talking about the specifics of this case and to operate at a slightly higher level of generality. I'm not sure I can do that with this next question, which goes back to your point, which I think -- in which I think you said: As long as the defendant has minimum contacts, there's no direct sales into the United States necessary and purposeful direction at the forum is sufficient to establish minimum contacts. Right? That's the point you made.

MR. LEVIN: It can be sufficient.

THE COURT: It is a way of demonstrating minimum contacts.

MR. LEVIN: Yes.

THE COURT: So my question for you is: To the extent that you're familiar with the record in this particular case, what's the purposeful direction?

MR. LEVIN: Well, we're not here to talk about the facts in this particular case.

THE COURT: I was worried you might say that. That's okay. That's fine. You don't have to address it. Your answer is consistent with your brief. I might ask one of the plaintiffs to stand up and answer just that question in a minute, but go ahead.

MR. LEVIN: What I was going to say was the purposeful direction that gets context through cases like Calder v. Jones, cases like the Western States Wholesale Natural Gas case, and they talk about there's a variety of requirements that go into it. I mean, so we're not talking about its application here, but we do think I would point the Court to those cases.

THE COURT: No, I'm familiar with the general principle that purposeful direction is sufficient to establish minimum contacts. I'm just wondering in this particular case what form that takes; but you're right, that's someone else's job this afternoon. It doesn't have to be your job.

MR. LEVIN: The last point I would make, unless the Court has further questions, is that defendants' submission, it disregards the way in which different parts of a conspiracy can work together.

you.

They're operating under the false premise that a conspiracy is the sum of its sales. However, as we pointed out in our submission, there's some conspiracies that don't involve sales at all, such as group boycotts in the United States where the conspirators don't have any sales in the United States, like group boycotts, that, nonetheless, have -- can have a direct -- substantial and direct effect in the United States and would be within the third prong.

And also the relevant acts in an antitrust conspiracy are not just the sales. It includes other types of acts, such as restricting production, creating an agreement to devise cheating, and so on. For example, if a defendant planned to sell in the United States but then didn't because pursuant to an agreement in a conspiracy, it can cause -- the act of foregoing the sale can cause a direct effect in the United States even without the actual sale.

In a conspiracy often the parts are interrelated and dependent. For example, an agreement to raise price, it wouldn't have any effect if everybody else is going to increase output. So there's often multiple parts to a conspiracy and the direct effect can come from any of them.

So if this Court has no more questions, we appreciate the ability to appear here today. Thank you.

THE COURT: I don't have any more questions. Thank

Would one of the plaintiffs -- before the reply happens, would one of the plaintiffs stand up and, limiting yourself carefully just to this question, would you answer the question of what you think -- if I find it necessary to go down this path, what the purposeful direction at the forum of the United States was on the part of the Irico defendants?

MR. RAPAWY: Yes, Your Honor. I think that we would say that the purposeful direction, if Your Honor goes down that path, is the fact that they knew and intended that they would increase prices in the United States through the operation of the cartel as shown by the meeting notes where U.S. dollar prices and U.S. market conditions were discussed.

THE COURT: Thank you.

Reply. Mr. Taladay.

MR. TALADAY: Your Honor, I'll speak just for a few minutes and reserve a few minutes for my colleague,

Mr. Plunkett.

THE COURT: Very good.

MR. TALADAY: First to speak to the DOJ points. The DOJ said several times in its brief that it takes no position on the facts of this case, but it did take a position on the facts of this case.

The DOJ investigated this case for more than six years.

It's a massive investigation into this market under these facts with these alleged co-conspirators. There was a leniency

applicant. There are numerous subpoenas. There were multiple cooperating defendants that they had access to, millions of documents, dozens of witness interviews, cooperation with foreign authorities who conducted dawn raids and prosecution and a guilty plea in the United States.

And based on this massive investigation, which the DOJ Antitrust Division conducted, the DOJ's position on the facts was that it took no action with respect to Irico.

THE COURT: But hold on. There are so many defendants in this case who were not criminally prosecuted who paid millions or many millions of dollars in settlement money, not out of motives of charity but because the evidence against them, presumably, was sufficient to cause them and their counsel's general to conclude they better pay the money rather than go to trial.

I'm taking too long to say this. I don't know that a nonprosecution decision weighs very much.

MR. TALADAY: Your Honor, it was beyond a nonprosecution decision. In fact, the DOJ did not subpoena Irico. It didn't request interviews of Irico employees. It didn't even contact U.S. counsel of record in this case for Irico. It made --

THE COURT: Why is the exercise of prosecutorial discretion relevant today?

MR. TALADAY: Well, Your Honor, if the U.S. DOJ

believed that there was, as they imply in their brief, an act by a nonsovereign that had direct effect in the United States, one would expect them to execute on their responsibility to at least investigate that, and I for one repudiate the suggestion that they failed in their obligation to discharge their responsibilities.

The --

THE COURT: Is your point that you think the Justice

Department changed its mind about either the sovereign status

of the Irico defendants or their culpability in the conspiracy?

MR. TALADAY: I'm sorry, Your Honor. I didn't hear the question.

THE COURT: Well, I just want to know where we're going. Is your point that you feel the United States has changed its mind either about the sovereign status of the Irico defendants or their culpability in the conspiracy?

MR. TALADAY: No, Your Honor, I don't think they have.

My point, Your Honor, is that actions speak louder than words,

and the actions of the DOJ on the facts of this case is that

they did nothing with respect to Irico because there was no

basis on which they should have done anything with respect to

Irico.

If there was a direct effect in the United States, they had every opportunity to identify that and to do something about it, at least to communicate with Irico about their

concern, and they did nothing. That's my point, Your Honor.

So for them to say that they take no position on the facts of this case I think is belied a little bit by the degree to which they investigated the facts of this case.

Now, Your Honor, just one other point. The direct sales point. To the extent that the DOJ or even that Your Honor had previously considered that FSIA direct effect could be based on the FTAIA, I believe, Your Honor, that is not properly directed, and the reason is that the FSIA is a jurisdictional statute. The FTAIA is not. The FSIA, therefore, requires minimum contacts; whereas, the FTAIA test does not.

And where you have purely foreign conduct by a party that has no minimum contacts with the United States, that is not sufficient to satisfy FSIA even if it's sufficient to satisfy the FTAIA.

I'll point Your Honor to two authorities. The first is the Restatement Fourth of the Foreign Relations Law,

Section 454. I believe it's paragraph 9 at page 17, which says (reading):

"No court has held that the commercial activity exception applies in a situation where a minimum contacts analysis would not be satisfied."

The other authority, Your Honor, would be Wescott versus Weisner, Northern District of California 2018, which is Westlaw 2463614.

You have to say the number again, please. 1 THE COURT: 24? 2 2463614 at page 4. MR. TALADAY: 3 THE COURT: Is this in the briefs? 4 MR. TALADAY: I don't know, Your Honor. I believe so. 5 THE COURT: Okay. 6 MR. TALADAY: And this goes to the point, Your Honor, 7 that conduct by co-conspirators, no matter how much that may 8 have been directed, or by any third party no matter how much 9 that would have been directed, is not sufficient to establish 10 11 conduct by another party. It says, Your Honor (reading): "Where conspiracy is alleged, an exercise of personal 12 jurisdiction must be based on forum-related acts that were 13 personally committed by each nonresident defendant and 14 15 acts of an alleged co-conspirator cannot be imputed to 16 establish jurisdiction over the third-party defendant." 17 That is simply to say, Your Honor, that actions by the parties that we may have sold to -- Irico may have sold to 18 outside the United States or acts by co-conspirators cannot be 19 imputed for purposes of minimum contacts or personal 20 21 jurisdiction. And, Your Honor, if you look at the corpus of cases that 22 talk about direct effect, the common thread of all of them is 23 that there is some privity between the act of the defendant and 24

the United States.

25

And, yes, Your Honor, there can be acts outside the 1 United States that give rise to an effect in the United States. 2 We would not disagree with that. That's what the third prong 3 clearly says. But in every case there is privity between that 4 5 act and the United States, between a purchaser in the United States, between a lender in the United States. 6 7 We don't have that here, Your Honor. There is no privity between any act of the Irico Group with respect to the subject 8 matter of this case and the United States. 9 I'll cede to my colleague. 10 11 THE COURT: Very good. Mr. Plunkett. MR. PLUNKETT: Thank you, Your Honor. 12 13 I'll quickly respond to some points raised by the DPP in a question that Your Honor asked about whether we're conceding 14 15 participation in a conspiracy. For purposes of jurisdiction, 16 we're not challenging that we attended the meetings that they 17 have submitted evidence of. Right. I just don't think that's in front 18 THE COURT: 19 of us today. 20 Yeah, it's not. MR. PLUNKETT: THE COURT: I don't take it as an admission. I'm just 21 22 saying that for today's motion, that's not what I'm seeing. 23 MR. PLUNKETT: It's not an admission.

But here is the part we do challenge: That any of that can constitute express aiming at the United States, which is

24

25

something they have to establish under Bristol-Myers Squibb and the Ninth Circuit precedent that requires in interpreting the direct-effects test to consider whether the minimum contacts are met.

There could not be a weaker showing by the DPPs of express aiming at the United States. They point to three e-mails that they say show that Irico intended to raise prices in the U.S.: Saveri Exhibits 19 and 26 and 30, and we outline those in our reply briefs. In one of these there's simply a reference to U.S. currency. There's no reference to the U.S. market. There's no statement by Irico. There's no indication that Irico was going to sell in the United States or that prices were being discussed. In the other two there's references to an exchange rate in U.S. dollars.

So that is the express aiming here. That is why that

Ninth Circuit precedent, which they are so desperate to say was

overruled by Weltover in the Supreme Court, doesn't apply.

Because if it does apply, if the Court considers personal

jurisdiction, they lose. They cannot show any express aiming

by these Chinese companies at the United States.

Going to organ status, briefly, I know Your Honor says that you're not persuaded by the public purposes of Irico Group.

THE COURT: That's a tough one for you.

MR. PLUNKETT: I -- so I'm not going to argue it.

THE COURT: Group you don't have to worry about. It's Display.

MR. PLUNKETT: Yeah. They conceded Group.

Display, I am worried about it after Your Honor's statement, but public purpose is only one of the factors. It's a multifactor test. We don't have to win all of the factors.

Here's the important point with Irico Display. The experts in this case, their own expert conceded the points that they make, which is that this is a largely privately held company where the shareholders have extensive rights. In fact, what their own expert said at deposition is that the percentage of shares retained, directly or indirectly, by the parent company varies but it is always sufficient to retain ultimate control.

There is a --

THE COURT: What does that really tell me? I'm not sure -- I'm having trouble getting my hands around that argument because reduced to its essence, that argument is sort of, well, you know, in China the percentage of ownership might say a certain thing, the documents, the corporate governance documents might say a certain thing, but actually who knows. That is only a slightly hyperbolic and hopefully not flip way, I think, of characterizing this argument, and it's your burden.

MR. PLUNKETT: It is our burden at this point, and let me explain what I mean.

THE COURT: So who knows it's not good for you?

MR. PLUNKETT: So organ status is always going to be a company that is held less than 50 percent, indirectly or directly, by the government. Because if it was held more than 50 percent, they're in like Flynn like Group is.

So here we have to consider the multifactor test, and this was discussed by the expert. There are many companies in China that are partially owned or controlled by the Chinese government. That has gone way down in the last 20 years.

Maybe 20 or 30 percent of them are.

But the point here is that China itself and Group and Display define Irico Display as state controlled, and that is not true of most companies in China. This is a unique situation.

The 2007 annual report of Display says that Group is the actual controller of Display. It would do me no good nor do I have time to go through the host of ways in which Group and the government control Display, but to me it is astounding the level of control.

It does not provide protection for 30 percent of the Chinese economy from liability in the United States because even if they're a foreign sovereign, if they cause a direct effect in the United States, they're liable. But when the company is state controlled, it ought to be found to be an organ under the FSIA.

I want to move on to two --

THE COURT: I'm hoping you'll address this point about -- in the -- you know, the three subparts, the third of which is direct effect. Could you identify some conduct that -- boy, I thought I made a clearer note and now it turns out my notes aren't very good.

MR. PLUNKETT: Well, I think --

THE COURT: I'll add a minute to your time just because I'm stalling up here. Hold on.

(Pause in proceedings.)

THE COURT: What falls under the third prong, commercial activity, but not under the first or second? That was Mr. Rapawy's question. I thought it was a good question.

MR. PLUNKETT: Well, in a contract case, it would be somebody entering -- somebody in another country entering into a contract with someone in a U.S. company and their conduct can cause a breach of that contract. In an antitrust case, I think there could be sales that could fall under either the first or the third.

THE COURT: Mr. Levin says in a group boycott case there would never be a direct effect using your test. It wasn't a bad point. What do you think of it?

MR. PLUNKETT: Well, let me think about that. If there's a group boycott, I don't know why there couldn't be a direct effect in the United States. It's conduct. The refusal

would be conduct. There could be an effect in the 1 United States. I think in that situation you'd end up with --2 because this is not the FTAIA --3 Get back to Mr. Taladay's privity point 4 THE COURT: 5 maybe. Should I? 6 MR. TALADAY: 7 MR. PLUNKETT: Yeah, sure. Absolutely. MR. TALADAY: Your Honor, to give you what I think is 8 a pretty clear example, if I'm a seller in Mexico and you're a 9 10 U.S. company, I come into the United States, I sell you a 11 product. That is, I think, the first exception. If you come to Mexico and I sell you a product to take 12 back to the United States, I think that's the third exception. 13 But if I sell to a store in Mexico and I have no further 14 15 communication or connection to the United States and Stuart 16 decides to go into the United States and sell or sells to you 17 to take to the United States, that's none of the exceptions, 18 Your Honor. All right. 19 THE COURT: 20 MR. PLUNKETT: But the real issue here is if you 21 interpret the third exception direct effects as allowing a 22 situation where a defendant participates in a global 23 conspiracy, raises prices, causes something here, they have no contacts with the United States, it's unconstitutional. 24

the statute -- that's the statutory construction canon that

25

matters here.

If it's interpreted that way, it's unconstitutional because the FSIA is the sole source of jurisdiction. So it's a completely different statute than the FTAIA.

They cite Sea Breeze. It was affirmed by the

Ninth Circuit. I would just encourage Your Honor to look at
the footnote where this is addressed in the Ninth Circuit. It
makes clear that the reason for finding a direct effect was
that a contract with a U.S. entity would have been breached.

It had nothing to do with the effects of a conspiracy. It
doesn't support their position.

THE COURT: Can you imagine a defendant, corporate defendant, that is resident in a country with no antitrust laws -- I don't know if there is such a country, but we'll imagine that there is one -- and they participate in a conspiracy to fix prices in a global market? So that we could all agree that while there might be debates about the level of effect, prices being what they are, if the conspiracy is effective, it will affect prices everywhere.

And the company, as I say, is in a country that doesn't have any antitrust laws. Could they ever be sued anywhere under your theory?

MR. PLUNKETT: Well, if they have no contact with another jurisdiction, I mean, it would depend on each jurisdiction's long-arm statutes and their own rules; but in

the United States, if it's a foreign sovereign, the problem -they would probably trip on this direct effects argument and
the need to show personal jurisdiction.

THE COURT: Right. Okay.

MR. PLUNKETT: There would probably be a need to show, as there is under any long-arm statute, especially now with Bristol-Myers Squibb, to show something that happened in the forum that is connected to the claim.

THE COURT: And if I go back more carefully through this reply brief, I'm going to -- I'm not going to have any trouble pulling apart the \$8 million in sales, am I? It's all laid out there like a surgeon's tool?

Mr. Taladay is nodding emphatically. Okay. Then I'm not going to worry about it.

MR. PLUNKETT: It is laid out there, but there's a very easy answer and it's actually what I wanted to conclude with, which is that all of the sales, every one of them, the samples, all of them, Irico (USA), all of them, everyone is CNEIECC.

And I don't want to be -- the reason we know that that's a problem for them is because there was one document of all the documents submitted to the Court where they said, "Hey, that's a hearsay. That's the official public record in China that shows that Group never had any ownership interest in CNEIECC."

And they object to it and don't want the Court to consider it

```
because it shows there's no U.S. sales and it pushes the Court
 1
     into this place where they can't win, where the only way they
 2
     can win is by saying, "We participated in a conspiracy and
 3
     here's some express aiming because U.S. currency is mentioned
 4
 5
     in these e-mails."
          Those sales don't matter, but it is set forth in the reply
 6
     brief why each of them doesn't matter independent of the fact
 7
     that they're not our sales.
 8
              THE COURT: Very good.
 9
10
              MR. PLUNKETT: Thank you, Your Honor.
11
              THE COURT:
                          Thank you.
          Thank you all for your very good arguments and the
12
     interesting briefing. These motions are under submission.
13
              THE CLERK: Court is in recess.
14
15
                   (Proceedings adjourned at 3:19 p.m.)
16
                                 ---000---
17
18
19
20
21
22
23
24
25
```

CERTIFICATE OF REPORTER I certify that the foregoing is a correct transcript from the record of proceedings in the above-entitled matter. DATE: Wednesday, June 12, 2019 g andergen Jo Ann Bryce, CSR No. 3321, RMR, CRR, FCRR U.S. Court Reporter